Insights & news

Belgium Prepares to Implement Regulation (EU) 2019/6 on Veterinary Medicinal Products

  • 10/09/2021
  • Articles

Earlier this week, Belgian plans for implementing Regulation (EU) 2019/6 on veterinary medicinal products and repealing Directive 2001/82/EC (the Vet Reg) were made partially publicly available pursuant to the notification procedure governing possible technical barriers to trade provided for by Directive (EU) 2015/1535. This Technical Regulation Information System or “TRIS” procedure allows both the European Commission and the EU Member States to review before their adoption technical regulations which Member States intend to introduce for products and Information Society services. The TRIS procedure thus created a mechanism to increase the likelihood that the proposed texts are compatible with EU law, including the Internal Market principles.
 
The European Commission’s TRIS platform now displays the text of a draft Law governing veterinary medicinal products (“Voorontwerp van Wet betreffende diergeneesmiddelen”/“Avant-projet de loi sur les médicaments vétérinaires” – the Draft Vet Lawsee, attached Dutch and French versions) which will be submitted to Parliament and is intended to apply on 28 January 2022, the date of application of the Vet Reg. As a Regulation the Vet Reg is directly applicable in EU Member States and, theoretically, does not require national implementation. However, as was the case for many Regulations across diverse fields of law, implementing measures also proved necessary for the Vet Reg. Accordingly, the Draft Vet Law contains an extensive set of detailed rules and provides for the prospect of even more elaborate implementing rules that will be enacted by Royal Decree.
 
The Draft Vet Law regulates a set of important issues, including clinical trials with veterinary medicinal products; marketing authorisations; post marketing authorisation measures; pharmacovigilance; the manufacturing, preparation, importation and exportation of veterinary medicinal products; wholesale and retail trade, including sales at a distance; parallel trade; publicity; inspection, supervision and criminal penalties; administrative settlements; and the processing of inspection data.
 
As a result of the Draft Vet Law, the Law of 25 March 1964 governing medicines will no longer apply to veterinary medicinal products and is for that reason made subject to a lot of modifications.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 19/07/2022
    • Articles

    European Commission Continues to Pursue "Gun Jumping" Merger Control Proceedings against Illumina and Grail

    On 20 August 2021, the European Commission (the Commission) said that it would investigate whether Illumina’s decision, made public on 18 August 2021, to acquire Grail pending the Commission’s review of that transaction under Regulation 139/2004 on the control of concentrations between undertakings (the Merger Regulation) is in breach of the “standstill obligation” provided for by Article 7, Merger Regulation. Pursuant to this provision, a concentration notifiable under the Merger Regulation must not be implemented until after the Commission has approved it (see, Van Bael & Bellis Life Sciences News and Insights of 24 August 2021).

    Read more
    • 15/07/2022
    • News

    European Commission Publishes Proposal for Regulation on Substances of Human Origin

    On 14 July 2022, the European Commission (the Commission) published its long-awaited Proposal for a Regulation on standards of quality and safety for substances of human origin intended for human application (COM(2022) 338 final; the proposed Regulation) and an accompanying Q&A document (see, attachments). The proposed Regulation updates the current regulatory framework to improve safety and quality standards applicable to substances of human origin (so-called SoHOs). SoHOs include blood, tissues, cells and any other substances of human origin like human breast milk and microbiota. SoHOs can be directly intended for human application but can also be used in preparations or in manufactured products. Article 2 of the proposed Regulation provides for a list of “SoHO activities” that fall within the scope of the proposed Regulation. The list includes activities such as donor recruitment, processing of SoHOs, distribution, import and export of SoHOs and human application of SoHOs.   The proposed Regulation will apply to all SoHOs. Only solid organs used for transplantation will remain regulated separately under the Organs Directive (Directive 2010/45/EU). In view of the broad definition of the term SoHOs, the proposed Regulation will be future-proof in the sense that it will automatically apply to new substances of human origin that can be applied to patients. A key aspect of the proposed Regulation is that it empowers the Commission to adopt implementing acts regarding patient, donor and offspring protection. However, in the absence of such implementing acts, “SoHO entities” (which are defined in Article 3(24) as “organisation[s] legally established in the Union that carr[y] out one or more of the SoHO activities”) will have to apply standards established by the European Centre for Disease Prevention and Control and the European Directorate for the Quality of Medicines & HealthCare of the Council of Europe. The aim is to ensure that technical rules applicable to SoHO activities remain updated and to avert the accumulation of obsolete rules which would stand in the way of novel SoHO-based treatments and new medical techniques. For purposes of enforcement, the Commission devised a supervision mechanism based on national Competent Authorities. Chapters II and III of the proposed Regulation are dedicated to, respectively, “Competent Authorities” and “SoHO Supervisory Activities”. The rules enable extensive coordination between the different national Competent Authorities and the Commission. According to the Commission, increased harmonisation in the field of SoHO activities between EU countries could bring significant improvements in treatments such as stem, cornea, or skin transplants. Facilitated exchanges of SoHOs could even save lives, especially for conditions like blood cancer for which blood supply is of critical importance. The proposed Regulation will now be discussed by the Council and the European Parliament. Once the final text is agreed, adopted and published, most of the provisions will take effect after a transition period of two years.

    Read more
    • 14/07/2022
    • Articles

    General Court Confirms European Commission's Power to Review Illumina-Grail Even Though EU and National Turnover Thresholds Are Not Reached

    Yesterday, the General Court of the European Union came down on the side of the European Commission (the Commission) in that agency’s dispute with genomics firm Illumina and held that the Commission has jurisdiction to examine Illumina's acquisition of cancer detection test start-up Grail, even though the transaction escapes the European and Member State turnover thresholds for review (case T-227/21, Illumina, Inc. v. European Commission – see, attachment).

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *